AlenCiken

the world's first Phase 3 oral insulin study

NASDAQ:ORMP   Oramed Pharmaceuticals Inc.
Oramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study

Randomization of patients in the world's first Phase 3 oral insulin study conducted under FDA approved protocol

Announced today that randomization of patients in its first Phase 3 study of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D) is under way. The study is being conducted in accordance with U.S. Food and Drug Administration (FDA) approved protocols.

Efficacy data will become available after all patients have completed the first 6-month treatment period.

finance.yahoo.com/ne...tiple-132500401.html

免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。